Table 1.
Characteristics of studies included in the meta-analysis on the effect of PCI on overall survival in resected SCLC
| Author [Ref] | Year | Country | Design | Accrual years | Follow-up time | Total Patients | PCI (%) | Stage | PCI dose | Adjuvant chemotherapy |
|---|---|---|---|---|---|---|---|---|---|---|
| Bischof 27 | 2007 | Germany | Retrospective | 1995-2006 | 29 (2-110) months | 39 | 21 (54.0%) | p-stage IA-IIB | 30Gy/15F | 35 (90.0%) received ≥ 4 cycles of ChT |
| Zhu H16 | 2014 | China | Retrospective | 2003-2009 | 39.4 (4.0-96.8) months | 193 | 67 (34.7%) | c-stage I-III | 25Gy/10F | All the patients received ChT, 164 (85.0%) patients received ≥ 4 cycles of ChT |
| Yokouchi 30 | 2015 | Japan | Retrospective | 2003-2013 | 25.5 (0.4-130.9) months | 156 | 13 (8.3%) | c-stage I-III | 25Gy/10F or 30Gy/15F | 100 (64.1%) received chemotherapy |
| Xu J17 | 2016 | China | Retrospective | 2006-2014 | Not reported | 349 | 115 (32.9%) | c-stage I-III | Not reported | 290 (83.1%) received ≥ 4 cycles of ChT |
| Yang C28 | 2016 | USA | Retrospective | 2003-2011 | Not reported | 954 | 99 (10.3%) | p-stage I | Not reported | 566 (59.3%) received chemotherapy |